NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Lab USA, Inc ("Rocket Lab" or the "Company") (NASDAQ:RKLB). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Pomerantz LLP is investigating claims on behalf of investors of BigBear.ai Holdings, Inc. ("BigBear" or the "Company") (NYSE:BBAI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Affirm Holdings, Inc. ("Affirm" or the "Company") (NASDAQ:AFRM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Polestar Automotive Holding UK PLC ("Polestar" or the "Company") (NASDAQ:PSNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against TELUS International (Cda) Inc. ("Telus" or the "Company") (NYSE:TIXT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against TFI International Inc. ("TFI" or the "Company") (NYSE:TFII). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

The U.S. equity market has struggled in the past few weeks, with the tech-heavy Nasdaq Composite index down by some 14% at one point from the recent high in December 2024. While the index has recently recovered, it's still in the correction zone (lower than 10% from the previous high).

NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Pomerantz LLP is investigating claims on behalf of investors of RLX Technology Inc. ("RLX" or the "Company") (NYSE:RLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XP Inc. ("XP" or the "Company") (NASDAQ:XP). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Pomerantz LLP is investigating claims on behalf of investors of iRobot Corporation ("iRobot" or the "Company") (NASDAQ:IRBT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Xponential Fitness, Inc. ("Xponential" or the "Company") (NYSE:XPOF). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Pliant Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , March 28, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Pliant Therapeutics, Inc. ("Pliant" or the "Company") (NASDAQ: PLRX).

9:50am: Stocks open lower Stocks opened lower on Friday as investors weighed economic data and awaited potential tariff announcements. The Dow Jones fell 193 points (0.5%) to 42,106, the S&P 500 declined 18 points (0.3%) to 5,675, and the Nasdaq dropped 75 points (0.4%) to 17,729.

Katapult Holdings, Inc. (NASDAQ:KPLT ) Q4 2024 Earnings Conference Call March 28, 2025 8:00 AM ET Company Participants Jennifer Kull - Vice President, Head of Investor Relations Orlando Zayas - Chief Executive Officer Derek Medlin - President and Chief Growth Officer Nancy Walsh - Chief Financial Officer Conference Call Participants Kyle Joseph - Stephens Anthony Chukumba - Loop Capital Markets Scott Buck - H.C. Wainwright Operator Thank you for standing by and welcome to the Katapult Holdings Fourth Quarter and Full-Year 2024 Earnings Conference Call.

BB's focus on opportunities in the IoT and cybersecurity space bodes well. Tough automotive backdrop and intense competition remain concerning.

YUMC doubles down on digitization, leveraging technology and Gen-AI to enhance customer experience and drive growth. Yet, an uncertain macro environment ails.

Quaker Chemical is set to offer advanced solutions by using Dipsol's product technologies and its end markets.

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Viatris To Contact Him Directly To Discuss Their Options If you suffered significant losses in Viatris stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , March 28, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS).